Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $28.52 Analyst target: $34.43 Upside: 20.72%
JanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for pain management. The company is headquartered in Las Vegas, Nevada.
See the full interactive analysis & chart →Informational only — not investment advice.